Treatment of psychoses with dibenzothiazepine antipsychotic

• US 20050171088A1
• Filed: 01/26/2005
• Published: 08/04/2005
• Est. Priority Date: 01/30/2004
• Status: Abandoned Application

• Current Assignee: Astrazeneca AB (Astrazeneca PLC)
• Original Assignee: Astrazeneca AB (Astrazeneca PLC)
• Inventors: McCoy, Robin, Brecher, Martin, Block, Gilbert, MacFadden, Wayne, Wilson, Ellis, Minkwitz, Margaret, Ault, Brian, Mullen, Jamie
• Application Number:
  US11/043,622
• Publication Number:
  US 20050171088A1
• Time in Patent Office: Days
• US Class Current: 514/211.130
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants

Abstract

The present invention provides methods for treating depression symptoms associated with bipolar disorder.

Claims

1. A method for treating depression symptoms of one or more mood disorders in a patient comprising administering to a patient a therapeutically effective amount of quetiapine or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein the pharmaceutically acceptable salt of quetiapine is quetiapine fumarate.

3. The method according to claim 1, wherein the depression symptom is anxiety.

4. The method according to claim 1, wherein the depression symptom is reduced sleep quality.

5. The method according to claim 1, wherein the depression symptom is reduced quality of life.

6. The method according to claim 1 wherein said quetiapine is administered at a dose from about 300 mg/day to about 600 mg/day for a patient.

7. The method according to claim 1 wherein said quetiapine is administered at a dose of about 300 mg/day.

8. The method according to claim 1 wherein said quetiapine is administered at a dose of about 600 mg/day.

9. The method according to claim 1 wherein said quetiapine is administered once daily.

10. The method according to claim 1, wherein the amount of quetiapine results in a low rate of treatment-emergent mania.

11. The method according to claim 1, wherein said mood disorder is bipolar disorder.

12. A method according to claim 11, wherein said bipolar disorder is bipolar I.

13. A method according to claim 11, wherein said bipolar disorder is bipolar II.

14. A method for treating depression symptoms of bipolar disorder comprising administering to a patient a therapeutically effective amount of a compound of Formula (I):

15. A method according to claim 14, wherein the pharmaceutically acceptable salt of quetiapine is quetiapine fumarate.

16. A monotherapeutic method of treating a patient for the depression symptoms of one or more mood disorders comprising administering to the patient a therapeutically effective amount of quetiapine or a pharmaceutically acceptable salt thereof.

17. A method according to claim 16, wherein the mood disorder is bipolar disorder.

18. A method according to claim 16, wherein the bipolar disorder is bipolar I.

19. A method according to claim 16, wherein the bipolar disorder is bipolar II.

20. A monotherapeutic method of treating a patient for the depression symptoms of bipolar disorder comprising administering to the patient a therapeutically effective amount of 2-[2-(4-dibenzo [b,ƒ

] [1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol fumarate.

21. A method for the treatment of depression symptoms by administering to a patient an antidepressant amount of a compound selected from quetiapine and a pharmaceutically acceptable salt thereof.

22. The use of a compound of quetiapine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating depression symptoms associated with one or more mood disorders in a patient.

23. The use of a compound of quetiapine or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating depression symptoms associated with bipolar disorder in a patient.